GSK Rebuts Teva’s ‘Doomsday Scenario’ On Skinny-Label Generics

Originator Urges US Supreme Court To Reject Review Of Indication Carve-Out Lawsuit

 
• By Dave Wallace

GSK has lodged its opposition to Teva’s bid to resurrect long-running US litigation over “skinny-label” indication carve-outs at the Supreme Court level, claiming that Teva’s warnings of a “doomsday scenario” for generics are overstated.

Doomsday Armageddon Apocalypse Planet Exploding
Teva’s “doomsday scenario” falls apart under scrutiny, GSK claims • Source: Shutterstock

GlaxoSmithKline has hit back at Teva’s attempt to have the US Supreme Court re-examine long-running litigation revolving around “skinny label” generics that carve out patented indications from their labels.

Earlier this year, Teva lost the latest round in its long-running battle with GSK over skinny-label generics, after the US Court of Appeals for the Federal Circuit

More from Legal & IP

More from Generics Bulletin